60 Degrees Pharma Launches Weekly ARAKODA Malaria Prevention on Runway Health
60 Degrees Pharmaceuticals has launched ARAKODA® (tafenoquine) for once-weekly malaria prevention on Runway Health’s telehealth platform, allowing U.S. travelers to obtain prescriptions and home delivery before departure. ARAKODA, FDA-approved in 2018 for adults, features a 16-day half-life and broad-spectrum dosing after an initial three-day loading phase.
1. Partnership with Runway Health
60 Degrees Pharmaceuticals has integrated ARAKODA® (tafenoquine) into Runway Health’s telehealth platform, enabling U.S. travelers to consult a licensed provider online, receive a prescription upon eligibility determination, and have the medication shipped to their address ahead of travel.
2. ARAKODA Clinical Profile
ARAKODA®, FDA-approved in 2018 for adults aged 18 and over, requires a three-day initial loading phase of 2×100 mg tablets followed by once-weekly dosing for up to six months, leveraging its 16-day half-life to cover broad-spectrum malaria prophylaxis.
3. Market and Access Implications
Online availability aims to streamline travel health planning for trips to malaria-endemic regions across Africa, Asia, South America and Oceania, potentially boosting ARAKODA uptake by offering a convenient alternative to daily antimalarial regimens and expanding the product’s distribution channel.